{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:21:51Z","timestamp":1774538511028,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T00:00:00Z","timestamp":1414627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ixekizumab, an anti\u2010<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201017A monoclonal antibody, demonstrated a high level of efficacy in moderate\u2010to\u2010severe plaque psoriasis (<jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and safety of open\u2010label ixekizumab in Japanese patients with moderate\u2010to\u2010severe <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>, erythrodermic psoriasis (<jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content>) and generalized pustular psoriasis (<jats:styled-content style=\"fixed-case\">GPP<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients received 160\u2010mg subcutaneous ixekizumab injection at Week 0, 80\u2010mg every 2\u00a0weeks through Week 12 and 80\u2010mg every 4\u00a0weeks through Week 24. Efficacy and safety are reported through 24\u00a0weeks; additional safety data are available for some patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 78 patients with <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>, 8 with <jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> and 5 with <jats:styled-content style=\"fixed-case\">GPP<\/jats:styled-content> enrolled. In <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content> patients, <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>75 and <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>90 response rates were 98.7% (77\/78) and 83.3% (65\/78) at Week 12 respectively. In <jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> patients, <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>75 and <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>90 were 100.0% (8\/8) and 62.5% (5\/8) and in <jats:styled-content style=\"fixed-case\">GPP<\/jats:styled-content> patients were 80.0% (4\/5) and 60.0% (3\/5). Overall, 84.0% (76\/91) had a treatment\u2010emergent <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content> through \u226524\u00a0weeks. There were no serious <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s, deaths, cases of tuberculosis or invasive fungal infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Limitations<\/jats:title><jats:p>No control group and small sample sizes, especially for <jats:styled-content style=\"fixed-case\">EP<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">GPP<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>By Week 12, nearly all patients with <jats:styled-content style=\"fixed-case\">PP<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> EP<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">GPP<\/jats:styled-content> achieved <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>75. The safety profile was consistent with reported results and no unexpected safety signals were observed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12773","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T06:49:39Z","timestamp":1414651779000},"page":"1148-1155","source":"Crossref","is-referenced-by-count":110,"title":["Efficacy and safety of open\u2010label ixekizumab treatment in Japanese patients with moderate\u2010to\u2010severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis"],"prefix":"10.1111","volume":"29","author":[{"given":"H.","family":"Saeki","sequence":"first","affiliation":[{"name":"Department of Dermatology Nippon Medical School Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ishii","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Morisaki","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Aoki","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly Japan K.K. Kobe Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.\u2010Y.","family":"Berclaz","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Heffernan","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company Indianapolis IN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00192.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0075-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109997"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_6_8_1","first-page":"815","article-title":"Practice Guidelines 2010 for generalized pustular psoriasis (GPP): Treatment guidelines incorporating TNF\u2010a inhibitor","volume":"120","author":"Iwatsuki K","year":"2010","journal-title":"Jpn J Dermatol B"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.034"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1246"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11633110-000000000-00000"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.361"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.230"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12773","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:50:38Z","timestamp":1695556238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,30]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/jdv.12773"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12773","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,30]]}}}